# A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus

> **NCT04682873** · PHASE3 · COMPLETED · sponsor: **Joint Stock Company "Farmak"** · enrollment: 592 (actual)

## Conditions studied

- Covid-19 Disease

## Interventions

- **DRUG:** Enisamium Iodide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04682873
- **Lead sponsor:** Joint Stock Company "Farmak"
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-15
- **Primary completion:** 2021-03-26
- **Final completion:** 2021-03-26
- **Target enrollment:** 592 (ACTUAL)
- **Last updated:** 2021-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04682873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04682873, "A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04682873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*